Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation

  • James S Gammie
  • Michael W A Chu
  • Volkmar Falk
  • Jessica R Overbey
  • Alan J Moskowitz
  • Marc Gillinov
  • Michael J Mack
  • Pierre Voisine
  • Markus Krane
  • Babatunde Yerokun
  • Michael E Bowdish
  • Lenard Conradi
  • Steven F Bolling
  • Marissa A Miller
  • Wendy C Taddei-Peters
  • Neal O Jeffries
  • Michael K Parides
  • Richard Weisel
  • Mariell Jessup
  • Eric A Rose
  • John C Mullen
  • Samantha Raymond
  • Ellen G Moquete
  • Karen O'Sullivan
  • Mary E Marks
  • Alexander Iribarne
  • Friedhelm Beyersdorf
  • Michael A Borger
  • Arnar Geirsson
  • Emilia Bagiella
  • Judy Hung
  • Annetine C Gelijns
  • Patrick T O'Gara
  • Gorav Ailawadi
  • CTSN Investigators

Abstract

BACKGROUND: Tricuspid regurgitation is common in patients with severe degenerative mitral regurgitation. However, the evidence base is insufficient to inform a decision about whether to perform tricuspid-valve repair during mitral-valve surgery in patients who have moderate tricuspid regurgitation or less-than-moderate regurgitation with annular dilatation.

METHODS: We randomly assigned 401 patients who were undergoing mitral-valve surgery for degenerative mitral regurgitation to receive a procedure with or without tricuspid annuloplasty (TA). The primary 2-year end point was a composite of reoperation for tricuspid regurgitation, progression of tricuspid regurgitation by two grades from baseline or the presence of severe tricuspid regurgitation, or death.

RESULTS: Patients who underwent mitral-valve surgery plus TA had fewer primary-end-point events than those who underwent mitral-valve surgery alone (3.9% vs. 10.2%) (relative risk, 0.37; 95% confidence interval [CI], 0.16 to 0.86; P = 0.02). Two-year mortality was 3.2% in the surgery-plus-TA group and 4.5% in the surgery-alone group (relative risk, 0.69; 95% CI, 0.25 to 1.88). The 2-year prevalence of progression of tricuspid regurgitation was lower in the surgery-plus-TA group than in the surgery-alone group (0.6% vs. 6.1%; relative risk, 0.09; 95% CI, 0.01 to 0.69). The frequencies of major adverse cardiac and cerebrovascular events, functional status, and quality of life were similar in the two groups at 2 years, although the incidence of permanent pacemaker implantation was higher in the surgery-plus-TA group than in the surgery-alone group (14.1% vs. 2.5%; rate ratio, 5.75; 95% CI, 2.27 to 14.60).

CONCLUSIONS: Among patients undergoing mitral-valve surgery, those who also received TA had a lower incidence of a primary-end-point event than those who underwent mitral-valve surgery alone at 2 years, a reduction that was driven by less frequent progression to severe tricuspid regurgitation. Tricuspid repair resulted in more frequent permanent pacemaker implantation. Whether reduced progression of tricuspid regurgitation results in long-term clinical benefit can be determined only with longer follow-up. (Funded by the National Heart, Lung, and Blood Institute and the German Center for Cardiovascular Research; ClinicalTrials.gov number, NCT02675244.).

Bibliografische Daten

OriginalspracheEnglisch
ISSN0028-4793
DOIs
StatusVeröffentlicht - 27.01.2022

Anmerkungen des Dekanats

Copyright © 2021 Massachusetts Medical Society.

PubMed 34767705